Yuanjun Li1,2, Yunfeng Hu1, Haipian Li3, Liehua Deng1. 1. a Department of Dermatology , the First Affiliated Hospital of Jinan University , Guangzhou , People's Republic of China. 2. b Department of Dermatology , Shanxi Children Hospital , Taiyuan , People's Republic of China. 3. c Department of Dermatology , Guangzhou Women and Children's Medical Center , Guangzhou , People's Republic of China.
Abstract
BACKGROUND: Pulsed dye laser (PDL) treatment has been shown to be effective for the management of ulcerated areas of hemangiomas. However, targeting deeper dermal lesions requires a laser system that penetrates more deeply than a PDL. Thus, we applied a dual-wavelength 595- and 1064-nm laser system to the treatment of ulcerated hemangiomas. MATERIALS AND METHODS: Twenty-two infants with ulcerated hemangiomas (mean are, 3.8 cm2) were reviewed. Ulcers were treated by debridement and the surface received 595-nm PDL treatment at 4-5 J/cm2 with a pulse width of 0.5 ms. Then, the remaining hemangioma excluding the ulcerated portion was treated with dual-wavelength laser. Laser treatment was repeated at two-week intervals until cutaneous healing was observed. RESULTS: Ulcerative lesions in 20 of the 22 patients (90.9%) healed entirely within 2 weeks following the first laser treatment. Two patients also required oral steroids, and one patient underwent two laser treatments. The follow-up period ranged from 6 to 24 months, and no evidence of recurrent ulceration or hemangioma regrowth was observed. CONCLUSIONS: Our findings confirm that PDL treatment leads to a rapid decrease in pain and initiation of the healing process and indicate that dual-wavelength laser treatment offers rapid healing with few adverse effects.
BACKGROUND: Pulsed dye laser (PDL) treatment has been shown to be effective for the management of ulcerated areas of hemangiomas. However, targeting deeper dermal lesions requires a laser system that penetrates more deeply than a PDL. Thus, we applied a dual-wavelength 595- and 1064-nm laser system to the treatment of ulcerated hemangiomas. MATERIALS AND METHODS: Twenty-two infants with ulcerated hemangiomas (mean are, 3.8 cm2) were reviewed. Ulcers were treated by debridement and the surface received 595-nm PDL treatment at 4-5 J/cm2 with a pulse width of 0.5 ms. Then, the remaining hemangioma excluding the ulcerated portion was treated with dual-wavelength laser. Laser treatment was repeated at two-week intervals until cutaneous healing was observed. RESULTS: Ulcerative lesions in 20 of the 22 patients (90.9%) healed entirely within 2 weeks following the first laser treatment. Two patients also required oral steroids, and one patient underwent two laser treatments. The follow-up period ranged from 6 to 24 months, and no evidence of recurrent ulceration or hemangioma regrowth was observed. CONCLUSIONS: Our findings confirm that PDL treatment leads to a rapid decrease in pain and initiation of the healing process and indicate that dual-wavelength laser treatment offers rapid healing with few adverse effects.